Nanoparticles to improve eye fluid drainage in glaucoma
Modulating aqueous humor outflow with engineered nanoparticles for glaucoma
This research uses tiny engineered particles that slowly release glaucoma medicine to help adults with glaucoma lower eye pressure.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical College of Wisconsin NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project ID | NIH-11311866 on NIH RePORTER |
What this research studies
From a patient perspective, researchers are creating highly branched dendrimer hydrogel nanoparticles that carry glaucoma drugs and release them at a steady, predictable rate. The particles are being designed to reach and act on the trabecular meshwork, the eye’s main drainage pathway, to reduce resistance to fluid outflow. The team will test different nanoparticle designs in the lab and in preclinical models to measure how well they improve outflow and lower intraocular pressure. The long-term aim is to move promising formulations toward human testing so they could replace or reduce the need for frequent eye drops.
Who could benefit from this research
Good fit: Adults (21+) with glaucoma and elevated intraocular pressure who need better pressure control or have trouble with current topical therapies would be the most likely candidates.
Not a fit: People with forms of glaucoma that do not involve trabecular outflow dysfunction (for example certain angle-closure glaucomas) or those unable to undergo topical or local ocular treatments may not benefit.
Why it matters
Potential benefit: If successful, this approach could lower eye pressure more effectively and for longer periods, potentially reducing the need for daily eye drops and lowering risk of vision loss.
How similar studies have performed: Previous nanoparticle-based eye delivery studies have shown promise in improving drug retention and lowering pressure in animal models, but using tunable dendrimer hydrogel particles specifically to target the trabecular meshwork is a newer, mostly preclinical approach.
Where this research is happening
Milwaukee, United States
- Medical College of Wisconsin — Milwaukee, United States (Active)
Researchers
- Principal investigator: Yang, Hu — Medical College of Wisconsin
- Study coordinator: Yang, Hu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.